Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1490070 | 0.95 | GPR119 (0.54) | GPR119FAAHHPGDKDM4EPKM | |
| SCHEMBL5279948 | 0.93 | GPR119 (0.49) | GPR119FAAHHPGDKDM4EPKM | |
| SCHEMBL310276 | 0.89 | HPGD (0.53) | GPR119FAAHHPGDKDM4EPKM | |
| SCHEMBL15085741 | 0.89 | GPR119 (0.59) | GPR119FAAHHPGDKDM4EPKM | |
| SCHEMBL32687738 | 0.88 | GPR119 (0.48) | GPR119FAAHHPGDKDM4EPKM | |
| SCHEMBL5292375 | 0.86 | NR1H2 (0.51) | GPR119FAAHHPGD | |
| SCHEMBL7512359 | 0.86 | GPR119 (0.56) | GPR119FAAHHPGDKDM4EPKM | |
| SCHEMBL1576008 | 0.86 | GPR119 (0.56) | GPR119FAAHHPGDKDM4EPKM | |
| SCHEMBL23499817 | 0.85 | GPR119 (0.57) | GPR119FAAHHPGDKDM4EPKM | |
| SCHEMBL20128944 | 0.85 | GPR119 (0.57) | GPR119FAAHHPGDKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2941427-B1 | NOVEL BENZODIOXANE-PIPERIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | PF MEDICAMENT (FR) | 2016-11-09 | — | — | EP | disclosed |
| US-20150336943-A1 | NOVEL BENZODIOXANE-PIPERIDINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS FOR TREATING NEUROPSYCHIATRIC DISORDERS | PIERRE FABRE MEDICAMENT (FR) | 2015-11-26 | — | — | US | disclosed |
| EP-2941427-A1 | NOVEL BENZODIOXANE-PIPERIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | Pierre Fabre Médicament (FR) | 2015-11-11 | — | — | EP | disclosed |
| WO-2014106660-A1 | NOVEL BENZODIOXANE-PIPERIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | PIERRE FABRE MEDICAMENT (FR) | 2014-07-10 | — | — | WO | disclosed |
| US-6040317-A | AN ANTIAGGLOMERANTS USEFUL IN THE PREVENTION AND TREATMENT OF DISEASES CAUSED BY THROMBUS FORMATION | MERCK & CO., INC. (US) | 2000-03-21 | — | — | US | disclosed |
| US-5880136-A | PREVENTING THROMBUS FORMATION | MERCK & CO., INC. (US) | 1999-03-09 | — | — | US | disclosed |
| US-5814643-A | ANTICOAGULANTS | MERCK & CO., INC. (US) | 1998-09-29 | — | — | US | disclosed |
| US-5786373-A | Fibrinogen receptor antagonists | MERCK & CO., INC. (US) | 1998-07-28 | — | — | US | disclosed |
| US-5658929-A | ANTICOAGULANTS | MERCK & CO., INC. (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0667773-A4 | FIBRINOGEN RECEPTOR ANTAGONISTS. | MERCK & CO INC (US) | 1996-09-25 | — | — | EP | disclosed |
| EP-0667773-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1995-08-23 | — | — | EP | disclosed |
| WO-1994008577-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1994-04-28 | — | — | WO | disclosed |
| US-5292756-A | Novel sulfonamide fibrinogen receptor antagonists | MERCK & CO., INC. (US) | 1994-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336943-A1 | NOVEL BENZODIOXANE-PIPERIDINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS FOR TREATING NEUROPSYCHIATRIC DISORDERS | HCRTR1, HCRTR2, OXSR1 | GPR119 1802/4885FAAH 485/4885HPGD 3771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.